Takeda Pharmaceutical (TKPHF) Equity Income (2017 - 2026)

Takeda Pharmaceutical's Equity Income history runs 10 years deep, the most recent figure standing at $25.5 million for Q1 2026.

• In Q1 2026, Equity Income rose 871.13% year-over-year to $25.5 million; the TTM figure through Mar 2026 stood at $42.0 million (down 10.99% YoY), while the FY2026 annual figure was $14.5 million, down 44.73% from the prior year.
• Equity Income was $25.5 million for Q1 2026 at Takeda Pharmaceutical, up from -$2.6 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $29.5 million in Q3 2024 to a low of -$15.6 million in Q4 2023.
• Historically, Equity Income has averaged $5.5 million across 5 years, with a median of $3.8 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Equity Income slumped 124.7% in 2025, then soared 871.13% in 2026.
• A 5-year view of Equity Income shows it stood at -$12.5 million in 2022, then declined by 24.41% to -$15.6 million in 2023, then soared by 167.64% to $10.5 million in 2024, then plunged by 124.7% to -$2.6 million in 2025, then surged by 1079.61% to $25.5 million in 2026.
• The last three Equity Income figures came in at $25.5 million (Q1 2026), -$2.6 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.